Overview of RPS20P4: Potential Drug Target Or Biomarker (G6226)

Target Name: RPS20P4

NCBI ID: G6226

RPS20P4

Other Name(s): RPS20_6_627 | Ribosomal protein S20 pseudogene 4 | RPS20B | ribosomal protein S20 pseudogene 4

Overview of RPS20P4: Potential Drug Target Or Biomarker

RPS20P4 (RPS20_6_627) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the Rho family of GTPases, which are a group of proteins that regulate protein-protein interactions and act as molecular machines. RPS20P4 has been shown to play a role in the regulation of cellular processes that are important for maintaining tissue structure and function, and it is potential drug target or biomarker.

Purpose of the Review

The purpose of this review is to provide an overview of RPS20P4, including its structure, function, and potential as a drug target or biomarker.

Structure

RPS20P4 is a 20 kDa protein that is expressed in the brain, heart, and kidneys. It has a molecular weight of 190 kDa and a calculated pI of 1.5. RPS20P4 is a member of the Rho family of GTPases, and it has a unique catalytic mechanism that involves the formation of a GTPase intermediate.

Function

RPS20P4 is involved in the regulation of several cellular processes that are important for maintaining tissue structure and function. It has been shown to play a role in the regulation of cell division, cell migration, and the formation of blood vessels.

In addition to its role in cell regulation, RPS20P4 has also been shown to be a potential drug target or biomarker. The RPS20P4 gene has been targeted for drug development due to its potential role in several diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

Drugs that target RPS20P4 have been shown to have therapeutic effects in animal models of these diseases. For example, studies have shown that inhibitors of RPS20P4 can reduce the growth of cancer cells and improve the survival of neurodegenerative disease model animals.

Potential Applications

RPS20P4 is a potential drug target or biomarker due to its involvement in several diseases. The development of drugs that target RPS20P4 could have a significant impact on the treatment of these diseases.

In addition to its potential as a drug target, RPS20P4 has also been shown to be a potential biomarker for several diseases. The regulation of RPS20P4 expression and function has been shown to be involved in the development and progression of several diseases, including cancer, neurodegenerative diseases, and cardiovascular disease.

Conclusion

RPS20P4 is a protein that is involved in the regulation of several cellular processes that are important for maintaining tissue structure and function. It is a member of the Rho family of GTPases and has a unique catalytic mechanism that involves the formation of a GTPase intermediate. The The potential of RPS20P4 as a drug target or biomarker has been shown in animal models of several diseases, including cancer, neurodegenerative diseases, and cardiovascular disease. Further studies are needed to fully understand the role of RPS20P4 in these diseases and to develop effective treatments.

Protein Name: Ribosomal Protein S20 Pseudogene 4

The "RPS20P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS20P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets